Resource Summary Report

Generated by SPARC SAWG on Jul 31, 2026

Critical Path Institute; Arizona; USA

RRID:SCR_011173
Type: Tool

Proper Citation

Critical Path Institute; Arizona; USA (RRID:SCR_011173)

Resource Information

URL: http://c-path.org/

Proper Citation: Critical Path Institute; Arizona; USA (RRID:SCR_011173)

Description: An independent, non-profit organization dedicated to bringing scientists from the FDA, industry and academia all together to collaborate and improve the drug development and regulatory process for medical products.

Abbreviations: C-Path

Synonyms: Critical Path Institute

Resource Type: institution

Resource Name: Critical Path Institute; Arizona; USA

Resource ID: SCR_011173

Alternate IDs: nlx_157876, Wikidata: Q5186651, grid.417621.7

Alternate URLs: https://ror.org/02mgtg880

Record Creation Time: 20220129T080302+0000

Record Last Update: 20260725T190713+0000

Ratings and Alerts

No rating or validation information has been found for Critical Path Institute; Arizona; USA.

No alerts have been found for Critical Path Institute; Arizona; USA.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at SPARC SAWG .

Nedelman J, et al. (2025) Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials. IJTLD open, 2(8), 464.

Starling MS, et al. (2025) The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making. Clinical pharmacology and therapeutics, 117(2), 343.

Wilk J, et al. (2025) A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies. CPT: pharmacometrics & systems pharmacology, 14(11), 1787.

Rutherford KM, et al. (2024) PomBase: a Global Core Biodata Resource-growth, collaboration, and sustainability. Genetics, 227(1).

Sundquist Beauman S, et al. (2023) Nurses' Knowledge, Communication Needs, and Future Directions in Neonatal Research: Results of an International Survey. Advances in neonatal care : official journal of the National Association of Neonatal Nurses, 23(4), 338.

Stephenson D, et al. (2022) Can Innovative Trial Designs in Orphan Diseases Drive Advancement of Treatments for Common Neurological Diseases? Clinical pharmacology and therapeutics, 111(4), 799.

Lyons MA, et al. (2021) Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design. CPT: pharmacometrics & systems pharmacology, 10(3), 211.

Chalkou K, et al. (2021) A two-stage prediction model for heterogeneous effects of treatments. Statistics in medicine, 40(20), 4362.

, et al. (2020) Abstract: Posters: 13th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 2020. The journal of prevention of Alzheimer's disease, 7(S1), S55.

Shahin MH, et al. (2020) Open Data Revolution in Clinical Research: Opportunities and Challenges. Clinical and translational science, 13(4), 665.

Soul JS, et al. (2019) Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric research, 85(7), 943.

Salaets T, et al. (2019) Development of a neonatal adverse event severity scale through a Delphi consensus approach. Archives of disease in childhood, 104(12), 1167.

Fostel JM, et al. (2008) Towards standards for data exchange and integration and their impact on a public database such as CEBS (Chemical Effects in Biological Systems). Toxicology and applied pharmacology, 233(1), 54.